Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alex Shimmings

Alexandra has more than 20 years' experience covering pharmaceutical and biotech R&D. An early interest in medicine, and a dawning realization that being a doctor was not for her, led to a degree in Biochemistry and Microbiology at the University of Leeds, and a move to London to pursue a career in medical journalism. Now Scrip's Managing Editor, Alex has held a variety of roles on the publication since starting as a science reporter in 1998. She instigated some of Scrip's signature features, such as the Pipeline Watch and New Active Substance lists, and also casts an editorial eye over the annual Scrip Awards. Alex's main work interests lie in novel drugs and pharmaceutical and biotech R&D, and she also enjoys medical history and current affairs.
Advertisement
Set Alert for Articles By Alex Shimmings

Latest From Alex Shimmings

Jobs Go At Shield Therapeutics As Failed Study Fallout Hits

Shield Therapeutics is to slash its workforce and is considering a possible sale in the wake of a failed Phase III study for its only marketed product, Ferracru, that should have given it access to the US market.

Companies Commercial

EU Delays For Portola As CHMP Trend Votes Go Good And Bad

Portola will have to rein in its European sales ambitions as the CHMP gives early verdicts on its Factor Xa inhibitor betrixaban and its reversal agent andexanet. 

Approvals Policy & Regulation

Pieris And Seattle Strike IO Deal

Pieris secures another deal for its novel Anticalin technology – this time with Seattle in immuno-oncology.

Deals Companies

Eight Clinical Trial Read-Outs To Look Out For In Early 2018

The first three months of the year should bring late-stage clinical trial read-outs for a range of novel products including Johnson & Johnson's esketamine, Esperion's bempedoic acid, ImmuPharma's Lupuzor and VBL's gene therapy for brain cancer.

Clinical Trials Research & Development

Scrip’s State Of The Pharma Industry Infographic

A snapshot of the pharma and biotech universe at the start of 2018.

Commercial Research & Development

10 First Approvals To Look Out For In 2018

Another hectic 12 months are anticipated at the US FDA as it is set to give its verdict on no fewer than 40 products in 2018. Here Scrip takes a look at 10 of the more interesting candidates approaching the market for the first time.

Approvals Commercial
See All
Advertisement
UsernamePublicRestriction

Register